Titre :
  • A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors
Auteur : Raymond, Éric E. ; Faivre, Sandrine S. ; Alexandre, Jérôme J. ; Goldwasser, François F. ; Besse-Hammer, Tatiana ; Awada, Ahmad ; Gianella-Borradori, Athos ; Jego, V. V. ; Trandafir, Lucia L. ; Rejeb, Narmyn N.
Informations sur la publication : Investigational new drugs, 32, 1, (page 94-103)
Statut de publication : Publié, 2014
Sujet CREF : Cancérologie
Pharmacologie
Mots-clés : Aurora kinase inhibitor
Mitosis
MSC1992371A
Neutropenia
Phase l
Targeted therapy
Mots-clés MeSH : Adult
Aged
Aged, 80 and over
Antineoplastic Agents -- adverse effects -- blood -- pharmacokinetics -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- blood -- pharmacokinetics -- therapeutic use
Demography
Deoxycytidine -- analogs & derivatives
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms -- blood -- drug therapy
Norbornanes -- adverse effects -- blood -- pharmacokinetics -- therapeutic use
Protein Kinase Inhibitors -- adverse effects -- blood -- pharmacokinetics -- therapeutic use
Pyrimidines -- adverse effects -- blood -- pharmacokinetics -- therapeutic use
Young Adult
Note : SCOPUS: ar.j
Langue :
  • Anglais
Identificateurs : urn:issn:0167-6997 
info:doi/10.1007/s10637-013-9950-y
info:pmid/23539344